Abu Dhabi Health Services Company “Seha”, a subsidiary of the “PureHealth” group, has succeeded in using radioactive iodine to treat thyroid cancer in a 54-year-old patient who suffers from the last stages of kidney disease.
This achievement represents an important advance in the use of radioactive iodine to treat a patient who requires dialysis during isolation and constitutes a new precedent in innovative, collaborative and safe health care practices.
The treatment process was carried out in cooperation between the specialists of the “Sheikh Khalifa Medical City” affiliated with “SEHA” and the “SEHA Center for Kidney Care” under the supervision of a group of experts in nuclear medicine, endocrinology, kidney care, dialysis services, environmental health and safety, and engineering.
This multidisciplinary approach was essential in facing the exceptional challenges resulting from the patient’s condition.
Radioactive iodine is an essential treatment for thyroid cancer in the post-operative stage and requires precise doses based on a gradual classification of the risks that the patient may face.
The multidisciplinary thyroid cancer team unanimously decided that the patient should undergo a total thyroidectomy and be treated with radioactive iodine after surgery, with a special focus on ensuring the safety and effectiveness of dialysis during the patient’s radiation isolation period.
#SEHA #succeeds #treating #thyroid #cancer #radioactive #iodine
